Search Results
Your search for AT matches 29239 pages
Showing 101 - 150Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
Modified FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
In a phase II trial (PASS-01) reported in the Journal of Clinical Oncology, Knox et al found similar progression-free survival with modified leucovorin, fluorouracil, irinotecan, oxaliplatin (mFOLFIRINOX) vs gemcitabine/nab-paclitaxel in patients with previously untreated metastatic pancreatic...
Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemoradiotherapy did not improve event-free survival in patients with unresected locally advanced...
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...
Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer. Study Details In the double-blind trial, patients with stage I...
Zidesamtinib Shows Activity in Pretreated and Tyrosine Kinase Inhibitor–Naive Patients With ROS1-Positive NSCLC
Zidesamtinib, an investigational oral, highly selective ROS1 tyrosine kinase inhibitor designed to overcome common resistance mechanisms and improve brain penetration, has demonstrated activity in both pretreated and tyrosine kinase inhibitor–naive patients with ROS1-positive non–small cell lung...
Neoadjuvant FOLFIRINOX vs Gemcitabine-Based Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma
In a Dutch phase III trial (PREOPANC-2) reported in The Lancet Oncology, Janssen et al found no difference in overall survival between patients receiving neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy for resectable or borderline resectable pancreatic ductal...
Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment
Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International. “This type of cancer, which is a result of...
Advanced or Metastatic Breast Cancer: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Disease
The U.S. Food and Drug Administration (FDA) has approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression after at least one line of...
Can Nicotinamide Reduce the Risk of Skin Cancer Development?
The dietary supplement nicotinamide has been recommended by dermatologists for people with a history of skin cancer since 2015, when a clinical study published by Chen et al in The New England Journal of Medicine including almost 400 participants showed that those who took the vitamin B3 derivative ...
Combination Treatment and Patient Selection for Relugolix vs Leuprolide
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses current guideline recommendations for the use of relugolix and leuprolide, relugolix as a combination backbone, and...
Oral vs Injectable Agents for Androgen-Deprivation Therapy in Prostate Cancer
Atish D. Choudhury, MD, PhD, a medical oncologist and clinical/translational investigator at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discusses forms of hormonal therapy for patients with prostate cancer, with a focus on the HERO trial, which evaluated oral...
Medical Imaging and Risk of Pediatric and Adolescent Hematologic Cancer
In a study reported in The New England Journal of Medicine, Smith-Bindman et al found that medical imaging among children was associated with a significantly increased risk of pediatric and adolescent hematologic cancer. The study involved data from a retrospective cohort of 3,724,623 children born ...
More Tattoos, Lower Risk of Melanoma? New Study Investigates
People with more than one tattoo session may have a decreased risk of developing melanoma—with one key caveat, according to research published by McCarty et al in the Journal of the National Cancer Institute. A team led by Jennifer Doherty, PhD, Huntsman Cancer Institute investigator, Co-Leader of ...
AYA Cancer Survivors Face Increased Social Risks
This year, an estimated 85,500 adolescents and young adults (AYAs) will be diagnosed with cancer in the United States, and about 9,380 AYAs will die from the disease. And while cancer survivorship is increasing for all age groups—there are now nearly 19 million cancer survivors in the United...
HPV Self-Sampling Collection Test Improved Cervical Cancer Screening Rates Among Asian American Women
Studies have shown that human papillomavirus (HPV) infection—especially with high-risk variants such as HPV16 and HPV18—is the primary cause of cervical cancer, accounting for about 95% of all cases. Although cervical cancer screening through Pap smear tests can detect the presence of precancerous...
Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated NSCLC: Overall Survival in MARIPOSA
As reported in The New England Journal of Medicine by Yang et al, the final overall survival analysis in the phase III MARIPOSA trial has shown significant benefit with amivantamab plus lazertinib vs osimertinib in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer...
Surgery for Early-Stage Cancer and Opioid Use
Curative-intent surgery for patients with early-stage cancer led to new, persistent, long-term opioid use in more than 1 in 10 opioid-naive veterans, according to the results of an observational study published in Cancer. The results of the study highlighted how necessary it is to develop new pain...
Perioperative Use of Nivolumab With or Without Ipilimumab for Resectable Diffuse Pleural Mesothelioma
Perioperative use of nivolumab with or without ipilimumab may prove to be of benefit for patients with resectable diffuse pleural mesothelioma, according to the findings of a phase II study published in Nature Medicine. Findings from the study were also presented during the International...
Does Early Pesticide Exposure Lead to Higher Mortality Risk in Pediatric ALL?
New study findings show that children with acute lymphoblastic leukemia (ALL) who were exposed to pesticides during their mother's pregnancy may have a higher risk of death, according to findings published in Cancers. “This study highlights that exposures in the home environment, even before a...
James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69
James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical complications from surgery in...
Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertinib—an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR—in patients with HER2-mutant advanced or metastatic non–small cell...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
ASCO Remembers Past President Harvey M. Golomb, MD, FASCO
ASCO is deeply saddened by the loss of past president Harvey M. Golomb, MD, FASCO, a pioneer in the study of interferon as cancer treatment. Dr. Golomb passed away on August 20, 2025; he was 82. From the beginning of his medical career, Dr. Golomb was a committed member of ASCO. He joined the...
AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
The 15th edition of the annual AACR Cancer Progress Report presents a mixed picture of the major advances in cancer care over the past year, including the approval of 20 new anticancer drugs, juxtaposed against the continuing rise in early-onset cancers and disparities in care as well as the...
Overall Survival Benefit Shown for Neoadjuvant Nivolumab Plus Chemotherapy in Non–Small Cell Lung Cancer
In the preplanned final analysis of the phase III CheckMate 816 trial, an overall survival benefit has been shown for neoadjuvant nivolumab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).1 Patients treated with the combination experienced an approximate 10%...
Osimertinib Plus Chemotherapy Significantly Prolongs Overall Survival in EGFR-Mutated Advanced NSCLC
The combination of the EGFR-targeting tyrosine kinase inhibitor osimertinib with platinum-based chemotherapy significantly improved overall survival as a first-line treatment for patients with EGFR-mutated, advanced, non–small cell lung cancer (NSCLC) compared with osimertinib monotherapy,...
Acute Cystitis May Signal Urogenital Cancer
Acute cystitis signaled the presence of urogenital cancers in middle-aged men and women, according to the results of a Swedish cohort study published in BMJ Public Health. Based on these findings, the researchers suggested that acute cystitis could be used as a clinical marker for urogenital...
Use of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors
In a phase II trial (Alliance A021202) reported in the Journal of Clinical Oncology, Bergsland et al found that pazopanib prolonged progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). However, as stated by the investigators, pazopanib will...
Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Tang et al found that metastasis-directed radiotherapy without systemic therapy was associated with good outcomes in patients with oligometastatic clear cell renal cell carcinoma. Study Details In the trial, 121 patients...
City of Hope Awarded $23.7 Million to Map Biomarkers in NSCLC
City of Hope® has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will help City of Hope to create a biomap of tumor changes that cause immunotherapy resistance in advanced ...
New Approvals for Thrombocytopenia, Lung Cancer, Brain Cancer, and Multiple Myeloma
BTK Inhibitor for Chronic Immune Thrombocytopenia: On September 2, 2025, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib (Wayrilz) tablets to treat adults with persistent or chronic immune thrombocytopenia (ITP) who have had an...
Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer
In an interim analysis of a phase II trial reported in JAMA Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs photon involved-field radiotherapy (IFRT) in patients who have breast cancer or non–small cell lung...
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes
In a preplanned 10-year analysis from the phase III PORTEC-3 trial reported in The Lancet Oncology, Post et al found that adjuvant chemoradiotherapy was associated with improved overall survival and recurrence-free survival vs radiotherapy in women with high-risk endometrial cancer. Study Details...
Oral Microbiota and Risk for Pancreatic Cancer
Investigators have found several oral bacteria and fungi associated with an increased risk for pancreatic cancer, according to findings published in JAMA Oncology. This cohort study seems to confirm a long-standing suspicion of the relationship between poor oral health and pancreatic cancer and...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy
Three leading national cancer organizations have issued an updated guideline on postmastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight...
Policy Review: HRQoL Data in Clinical Trials for Advanced Cancer
A new policy review published by Tannock et al in The Lancet Oncology emphasizes the critical role of health-related quality-of-life (HRQoL) data in the evaluation of treatments for people with advanced cancer. The publication highlights the importance of having standardized responder criteria when ...
Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a U.S. two-center phase III trial (MC1675) reported in The Lancet Oncology, Ma et al found that de-escalated adjuvant radiotherapy was associated with a reduced cumulative, chronic grade ≥ 3 toxicity rate at 3 to 24 months after radiotherapy compared with standard adjuvant treatment in patients...
Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer
In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therapy improved radiographic progression-free survival in patients with oligometastatic...
Study Finds Insufficient Evidence Demonstrating Clinical Benefit of Multicancer Detection Tests
The U.S. Preventive Services Task Force currently recommends average-risk screening for four cancer types, including colorectal, cervical, breast, and lung cancer (for those with a sufficient smoking history). Despite this, approximately 70% of cancer-related deaths in the United States are due to...
Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO
Chronic myeloid leukemia (CML) is one of the success stories among the hematologic malignancies. Now, with decades of data informing its management, it is time to change some of the practices to which clinicians have become accustomed, said leukemia expert Hagop M. Kantarjian, MD, FASCO, Professor...
Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act
Research published by Zheng et al in Health Affairs Scholar found that the passage of the government price-setting provisions of the Inflation Reduction Act (IRA) was associated with a broad decline in industry-funded oncology trials after first U.S. Food and Drug Administration approval, with...
Incorporating Family Caregivers Into Shared Decision-Making for Patients With Cancer
In a recent study published in JCO Oncology Practice, Steffensen et al examined the process of shared decision-making (SDM) in which clinicians and patients collaborate to make health-care decisions according to the patients’ values, preferences, and medical needs. Although many seriously ill...
Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds
A retrospective cohort study conducted by Dessinioti et al and published in JAMA Dermatology found that, in cases of melanoma in situ, diagnostic excisional biopsy achieving clear margins may be sufficient for treatment. “No local recurrences, metastasis, or melanoma-specific death were observed...
Is TBI Associated With Malignant Brain Tumors?
The results of a retrospective cohort study published in JAMA Network Open revealed an association between having a history of moderate to severe traumatic brain injury (TBI) and the risk of developing malignant brain tumors in adult civilians from the United States. Marini et al confirmed the...
New Liquid Biopsy Test for Early Detection of Head and Neck Cancers
According to the American Cancer Society (ACS), human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) is the most common type of HPV-related malignancy in the United States. In 2025, ACS estimates there will be 59,660 diagnoses of mouth and throat cancers, and about...
Benmelstobart Plus Anlotinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
In an interim analysis of a Chinese phase III trial (ETER100) reported in The Lancet Oncology, Zhou et al found that the combination of the PD-L1 inhibitor benmelstobart and anlotinib improved progression-free survival vs sunitinib in the first-line treatment of advanced clear cell renal cell...
Naval G. Daver, MD, and Uma Borate, MBBS, Debate Lower-Intensity Regimens in AML
Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engaged in at the SOHO meeting. They discuss concomitant vs sequential use of lower-intensity regimens in ...
